BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 37259259)

  • 21. Outcomes of Childhood Noninfant Acute Lymphoblastic Leukemia With 11q23/
    Attarbaschi A; Möricke A; Harrison CJ; Mann G; Baruchel A; De Moerloose B; Conter V; Devidas M; Elitzur S; Escherich G; Hunger SP; Horibe K; Manabe A; Loh ML; Pieters R; Schmiegelow K; Silverman LB; Stary J; Vora A; Pui CH; Schrappe M; Zimmermann M;
    J Clin Oncol; 2023 Mar; 41(7):1404-1422. PubMed ID: 36256911
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The early achievement of measurable residual disease negativity in the treatment of adults with Philadelphia-negative B-cell acute lymphoblastic leukemia is a strong predictor for survival.
    Yilmaz M; Kantarjian H; Wang X; Khoury JD; Ravandi F; Jorgensen J; Short NJ; Loghavi S; Cortes J; Garcia-Manero G; Kadia T; Sasaki K; Konopleva M; Takahashi K; Wierda W; Jain N; Verstovsek S; Estrov Z; Bose P; Pierce S; Garris R; O'Brien S; Jabbour E
    Am J Hematol; 2020 Feb; 95(2):144-150. PubMed ID: 31682008
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Correction to: FLT3 inhibitor lestaurtinib plus chemotherapy for newly diagnosed KMT2A-rearranged infant acute lymphoblastic leukemia: Children's Oncology Group trial AALL0631.
    Brown PA; Kairalla JA; Hilden JM; Dreyer ZE; Carroll AJ; Heerema NA; Wang C; Devidas M; Gore L; Salzer WL; Winick NJ; Carroll WL; Raetz EA; Borowitz MJ; Small D; Loh ML; Hunger SP
    Leukemia; 2021 May; 35(5):1527. PubMed ID: 33846544
    [No Abstract]   [Full Text] [Related]  

  • 24. CD49f protein expression varies among genetic subgroups of B lymphoblastic leukemia and is distinctly low in KMT2A-rearranged cases.
    Collins K; Cardinali JL; Mnayer LO; DiGiuseppe JA
    Cytometry B Clin Cytom; 2021 Mar; 100(2):243-248. PubMed ID: 31894899
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Blinatumomab Added to Chemotherapy in Infant Lymphoblastic Leukemia.
    van der Sluis IM; de Lorenzo P; Kotecha RS; Attarbaschi A; Escherich G; Nysom K; Stary J; Ferster A; Brethon B; Locatelli F; Schrappe M; Scholte-van Houtem PE; Valsecchi MG; Pieters R
    N Engl J Med; 2023 Apr; 388(17):1572-1581. PubMed ID: 37099340
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Relationship between subtype-specific minimal residual disease level and long-term prognosis in children with acute lymphoblastic leukemia.
    Huang XT; Wang CJ; Gao C; Xue TL; Zhao ZJ; Wang TY; Wu MY; Cui L; Zhang RD; Li ZG
    Ann Hematol; 2024 Mar; ():. PubMed ID: 38494553
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Outcome of Infants Younger Than 1 Year With Acute Lymphoblastic Leukemia Treated With the Interfant-06 Protocol: Results From an International Phase III Randomized Study.
    Pieters R; De Lorenzo P; Ancliffe P; Aversa LA; Brethon B; Biondi A; Campbell M; Escherich G; Ferster A; Gardner RA; Kotecha RS; Lausen B; Li CK; Locatelli F; Attarbaschi A; Peters C; Rubnitz JE; Silverman LB; Stary J; Szczepanski T; Vora A; Schrappe M; Valsecchi MG
    J Clin Oncol; 2019 Sep; 37(25):2246-2256. PubMed ID: 31283407
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Azacitidine as epigenetic priming for chemotherapy is safe and well-tolerated in infants with newly diagnosed KMT2A-rearranged acute lymphoblastic leukemia: Children's Oncology Group trial AALL15P1.
    Guest EM; Kairalla JA; Devidas M; Hibbitts E; Carroll AJ; Heerema NA; Kubaney HR; August MA; Ramesh S; Yoo B; Farooqi MS; Pauly MG; Wechsler DS; Miles RR; Reid JM; Kihei CD; Gore L; Raetz EA; Hunger SP; Loh ML; Brown PA
    Haematologica; 2024 Jun; ():. PubMed ID: 38867582
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Minimal residual disease monitoring and preemptive immunotherapies for frequent 11q23 rearranged acute leukemia after allogeneic hematopoietic stem cell transplantation.
    Liu J; Zhang XH; Xu LP; Wang Y; Yan CH; Chen H; Chen YH; Han W; Wang FR; Wang JZ; Cheng YF; Qin YZ; Liu KY; Huang XJ; Zhao XS; Mo XD
    Ann Hematol; 2021 May; 100(5):1267-1281. PubMed ID: 33712867
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Incidence and prognostic value of central nervous system involvement in infants with B-cell precursor acute lymphoblastic leukemia treated according to the MLL-Baby protocol.
    Popov A; Tsaur G; Permikin Z; Fominikh V; Verzhbitskaya T; Riger T; Demina A; Shorikov E; Kustanovich A; Movchan L; Streneva O; Khlebnikova O; Makarova O; Arakaev O; Solodovnikov A; Boichenko E; Kondratchik K; Ponomareva N; Lapotentova E; Aleinikova O; Miakova N; Novichkova G; Karachunskiy A; Fechina L
    Pediatr Blood Cancer; 2022 Sep; 69(9):e29860. PubMed ID: 35713168
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Minimal residual disease is an important predictive factor of outcome in children with relapsed 'high-risk' acute lymphoblastic leukemia.
    Paganin M; Zecca M; Fabbri G; Polato K; Biondi A; Rizzari C; Locatelli F; Basso G
    Leukemia; 2008 Dec; 22(12):2193-200. PubMed ID: 18754029
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Predictive value of minimal residual disease in Philadelphia-chromosome-positive acute lymphoblastic leukemia treated with imatinib in the European intergroup study of post-induction treatment of Philadelphia-chromosome-positive acute lymphoblastic leukemia, based on immunoglobulin/T-cell receptor and BCR/ABL1 methodologies.
    Cazzaniga G; De Lorenzo P; Alten J; Röttgers S; Hancock J; Saha V; Castor A; Madsen HO; Gandemer V; Cavé H; Leoni V; Köhler R; Ferrari GM; Bleckmann K; Pieters R; van der Velden V; Stary J; Zuna J; Escherich G; Stadt UZ; Aricò M; Conter V; Schrappe M; Valsecchi MG; Biondi A
    Haematologica; 2018 Jan; 103(1):107-115. PubMed ID: 29079599
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Clinical significance of dynamic monitoring the minimal residual disease in childhood B-lineage acute lymphoblastic leukemia by multiparameter flow cytometry].
    Guo DD; Zhao WL; Zhang YL; Pang L; Che L; He HL; Chai YH; Ji ZH; Ji XQ
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2012 Dec; 20(6):1346-51. PubMed ID: 23257430
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinicopathologic and prognostic features of TdT-negative pediatric B-lymphoblastic leukemia.
    Klairmont MM; Zhou Y; Cheng C; Pui CH; Jeha S; Gruber TA; Liu Y; Inaba H; Choi JK
    Mod Pathol; 2021 Nov; 34(11):2050-2054. PubMed ID: 34148065
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cryptic recurrent ACIN1-NUTM1 fusions in non-KMT2A-rearranged infant acute lymphoblastic leukemia.
    Pincez T; Landry JR; Roussy M; Jouan L; Bilodeau M; Laramée L; Couture F; Sinnett D; Gendron P; Hébert J; Oligny L; Rouette A; Tran TH; Wilhelm BT; Bittencourt H; Cellot S
    Genes Chromosomes Cancer; 2020 Feb; 59(2):125-130. PubMed ID: 31515871
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Monitoring of minimal residual disease in children with acute lymphoblastic leukemia and its prognostic significance].
    Xu XJ; Tang YM; Song H; Shi SW; Yang SL; Shen HQ; Wei J; Xu WQ; Pan BH; Zhao FY
    Zhonghua Er Ke Za Zhi; 2010 Mar; 48(3):180-4. PubMed ID: 20426951
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children's Oncology Group study.
    Borowitz MJ; Devidas M; Hunger SP; Bowman WP; Carroll AJ; Carroll WL; Linda S; Martin PL; Pullen DJ; Viswanatha D; Willman CL; Winick N; Camitta BM;
    Blood; 2008 Jun; 111(12):5477-85. PubMed ID: 18388178
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Clinical Significance of Minimal Residual Disease in Risk Stratification and Prognosis of Childhood B-lineage Acute Lymphoblastic Leukemia].
    An FY; Zhang SH; Kong LJ; Liang Y; Xu JX; He HL; Chai YH; Zhao WL
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Jun; 25(3):729-735. PubMed ID: 28641626
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical significance of novel subtypes of acute lymphoblastic leukemia in the context of minimal residual disease-directed therapy.
    Jeha S; Choi J; Roberts KG; Pei D; Coustan-Smith E; Inaba H; Rubnitz JE; Ribeiro RC; Gruber TA; Raimondi SC; Karol SE; Qu C; Brady SW; Gu Z; Yang JJ; Cheng C; Downing JR; Evans WE; Relling MV; Campana D; Mullighan CG; Pui CH
    Blood Cancer Discov; 2021 Jul; 2(4):326-337. PubMed ID: 34250504
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Detection of minimal residual disease identifies differences in treatment response between T-ALL and precursor B-ALL.
    Willemse MJ; Seriu T; Hettinger K; d'Aniello E; Hop WC; Panzer-Grümayer ER; Biondi A; Schrappe M; Kamps WA; Masera G; Gadner H; Riehm H; Bartram CR; van Dongen JJ
    Blood; 2002 Jun; 99(12):4386-93. PubMed ID: 12036866
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.